Humacyte, Inc. Common Stock (HUMA) Stock Price

HUMAStock

$0.70−58.09%52W

Market Cap$194.79M

P/E—

PEG Ratio—

Div yield—

Beta2.54

HUMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-49.93%

Price vs S&P 500 (4W)1.94%

VGM Score36.49

Book Value / Share (Quarterly)$0.05

P/TBV (Annual)2.23x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.38%

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)-43.05%

Gross Margin (TTM)-563.56%

Net Profit Margin (TTM)-3494.64%

EPS (TTM)$-0.57

10-Day Avg Trading Volume14.50M

EPS Excl Extra (TTM)$-0.57

Revenue Growth (5Y)-19.92%

EPS (Annual)$-0.26

ROI (Annual)-60.09%

Gross Margin (Annual)-376.05%

Net Profit Margin (5Y Avg)-2142.40%

Cash / Share (Quarterly)$0.22

Revenue Growth QoQ (YoY)-4.26%

ROA (Last FY)-35.09%

Revenue Growth TTM (YoY)231.72%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-451.43%

Operating Margin (TTM)-6205.71%

Cash Flow / Share (Annual)$-0.55

P/B Ratio12.76x

P/B Ratio (Quarterly)11.59x

Net Income / Employee (Annual)$-221,900

EV / Revenue (TTM)96.60x

Net Interest Coverage (TTM)-78.58x

ROA (TTM)-85.38%

EV / EBITDA (TTM)5.30x

EPS Incl Extra (Annual)$-0.26

Current Ratio (Annual)3.69x

Quick Ratio (Quarterly)3.03x

3-Month Avg Trading Volume9.61M

52-Week Price Return-58.09%

Revenue / Employee (TTM)$9,300

Tangible BV / Share (Quarterly)$0.36

P/S Ratio (Annual)72.77x

Asset Turnover (Annual)0.02x

52-Week High$2.55

Operating Margin (5Y Avg)-4737.98%

EPS Excl Extra (Annual)$-0.26

CapEx CAGR (5Y)22.54%

26-Week Price Return-38.69%

Quick Ratio (Annual)2.78x

13-Week Price Return-35.08%

Total Debt / Equity (Annual)20.86x

Current Ratio (Quarterly)3.93x

Enterprise Value$165.66M

Revenue / Share Growth (5Y)-26.49%

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$11,100

Pretax Margin (Annual)-2003.58%

Cash / Share (Annual)$0.26

3-Month Return Std Dev123.38%

Net Income / Employee (TTM)$-530,400

ROE (Last FY)-1313.38%

Net Interest Coverage (Annual)-25.13x

EPS Basic Excl Extra (Annual)$-0.26

Receivables Turnover (TTM)3.72x

Total Debt / Equity (Quarterly)5.67x

EPS Incl Extra (TTM)$-0.57

Receivables Turnover (Annual)15.70x

ROI (TTM)-103.02%

P/S Ratio (TTM)86.47x

Pretax Margin (5Y Avg)-2142.40%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$1.13

Price vs S&P 500 (52W)-76.40%

Year-to-Date Return-31.09%

5-Day Price Return13.84%

EPS Normalized (Annual)$-0.26

ROA (5Y Avg)-48.93%

Net Profit Margin (Annual)-2003.58%

Month-to-Date Return1.35%

Cash Flow / Share (TTM)$-0.79

EBITD / Share (Annual)$-0.78

Operating Margin (Annual)-6398.63%

LT Debt / Equity (Annual)11.40x

ROI (5Y Avg)-61.19%

LT Debt / Equity (Quarterly)3.09x

EPS Basic Excl Extra (TTM)$-0.57

P/TBV (Quarterly)7.06x

P/B Ratio (Annual)59.62x

Inventory Turnover (TTM)1.29x

Pretax Margin (TTM)-3494.64%

Book Value / Share (Annual)$0.02

Price vs S&P 500 (13W)-37.87%

Beta2.54x

Revenue / Share (TTM)$0.01

ROE (TTM)-1278.91%

52-Week Low$0.53

vGradeD

gGradeC

mGradeD

vgmGradeD

HUMA Earnings Surprise History

Q2 25-0.24est. -0.18

Q3 25-0.11est. -0.16

Q4 25-0.13est. -0.14

Q1 26-0.09est. -0.12

Q2 26-0.16est. -0.10

HUMA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.08

4.09

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
HUMAHumacyte, Inc. Common Stock	D	C	D	$0.70
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Humacyte, Inc. Common Stock

Humacyte develops acellular bioengineered human tissues for therapeutic applications in vascular disease, peripheral arterial disease, dialysis access, and organ reconstruction. The company's tissue engineering platform aims to create universally implantable solutions that reduce rejection risk and address significant unmet medical needs across multiple therapeutic areas.